- Home
- BCAB vs SCYX Comparison
BCAB vs SCYX Comparison
Compare BCAB & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- SCYX
- Stock Information
- Founded
- BCAB 2007
- SCYX 1999
- Country
- BCAB United States
- SCYX United States
- Employees
- BCAB N/A
- SCYX N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- BCAB Health Care
- SCYX Health Care
- Exchange
- BCAB Nasdaq
- SCYX Nasdaq
- Market Cap
- BCAB 91.4M
- SCYX 76.7M
- IPO Year
- BCAB 2020
- SCYX 2014
- Fundamental
- Price
- BCAB $1.68
- SCYX $1.61
- Analyst Decision
- BCAB Strong Buy
- SCYX Buy
- Analyst Count
- BCAB 3
- SCYX 1
- Target Price
- BCAB $8.67
- SCYX N/A
- AVG Volume (30 Days)
- BCAB 571.3K
- SCYX 172.2K
- Earning Date
- BCAB 11-05-2024
- SCYX 11-11-2024
- Dividend Yield
- BCAB N/A
- SCYX N/A
- EPS Growth
- BCAB N/A
- SCYX N/A
- EPS
- BCAB N/A
- SCYX N/A
- Revenue
- BCAB N/A
- SCYX $9,666,000.00
- Revenue This Year
- BCAB N/A
- SCYX N/A
- Revenue Next Year
- BCAB N/A
- SCYX $126.72
- P/E Ratio
- BCAB N/A
- SCYX N/A
- Revenue Growth
- BCAB N/A
- SCYX N/A
- 52 Week Low
- BCAB $1.14
- SCYX $1.26
- 52 Week High
- BCAB $4.02
- SCYX $3.66
- Technical
- Relative Strength Index (RSI)
- BCAB 45.55
- SCYX 52.59
- Support Level
- BCAB $1.72
- SCYX $1.33
- Resistance Level
- BCAB $1.85
- SCYX $1.66
- Average True Range (ATR)
- BCAB 0.13
- SCYX 0.10
- MACD
- BCAB -0.02
- SCYX 0.04
- Stochastic Oscillator
- BCAB 10.34
- SCYX 87.50
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.